Drugs / DSXS 1538b
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02933502 | Jul 2016 → Sep 2017 | psoriasis | Sun Pharmaceutical Industries, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DSXS 1538b | “An Open-label, Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use Treatment With DSXS 1538b Topical Product Applied Once-daily in Patients With...” NCT02933502 ↗ |
| Route | Topical | “DSXS 1538b Topical Product Applied Once-daily” NCT02933502 ↗ |